China Healthcare Sector's Out-Licensing Set to Stay Strong -- Market Talk

Dow Jones12-16 17:31

0931 GMT - Innovation in China's healthcare sector should remain a key theme for 2026 despite recent underperformance, which Nomura analyst Jialin Zhang attributes to profit-taking. Zhang expects out-licensing activity to stay strong, supported by continued research and development investment, sustained cost and efficiency advantages over overseas peers, and fewer geopolitical hurdles following the recent U.S.-China trade truce. Zhang says it is critical to monitor the clinical progress of out-licensed assets next year, including data readouts and the speed of clinical trials. RNAi-based therapies could drive the next wave of out-licensing after weight-loss and oncology treatments, he adds, with IPO filings from RNAi companies potentially drawing further investor interest to the segment. Nomura tips Hengrui, Innovent, BeOne Medicines, Wuxi XDC and Mindray as its sector picks. (jason.chau@wsj.com)

(END) Dow Jones Newswires

December 16, 2025 04:31 ET (09:31 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591600991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591600991","market":"us","top_or_hot":-1,"title":"China Healthcare Sector's Out-Licensing Set to Stay Strong -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0931 GMT - Innovation in China's healthcare sector should remain a key theme for 2026 despite recent underperformance, which Nomura analyst Jialin Zhang attributes to profit-taking. Zhang expects out-licensing activity to stay strong, supported by continued research and development investment, sustained cost and efficiency advantages over overseas peers, and fewer geopolitical hurdles following the recent U.S.-China trade truce. Zhang says it is critical to monitor the clinical progress of out-licensed assets next year, including data readouts and the speed of clinical trials. RNAi-based therapies could drive the next wave of out-licensing after weight-loss and oncology treatments, he adds, with IPO filings from RNAi companies potentially drawing further investor interest to the segment. Nomura tips Hengrui, Innovent, BeOne Medicines, Wuxi XDC and Mindray as its sector picks. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 04:31 ET (09:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Healthcare Sector's Out-Licensing Set to Stay Strong -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Healthcare Sector's Out-Licensing Set to Stay Strong -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-16 17:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0931 GMT - Innovation in China's healthcare sector should remain a key theme for 2026 despite recent underperformance, which Nomura analyst Jialin Zhang attributes to profit-taking. Zhang expects out-licensing activity to stay strong, supported by continued research and development investment, sustained cost and efficiency advantages over overseas peers, and fewer geopolitical hurdles following the recent U.S.-China trade truce. Zhang says it is critical to monitor the clinical progress of out-licensed assets next year, including data readouts and the speed of clinical trials. RNAi-based therapies could drive the next wave of out-licensing after weight-loss and oncology treatments, he adds, with IPO filings from RNAi companies potentially drawing further investor interest to the segment. Nomura tips Hengrui, Innovent, BeOne Medicines, Wuxi XDC and Mindray as its sector picks. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 04:31 ET (09:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128526141.USD","symbol_name":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591600991","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591600991","pubTimestamp":1765877460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0931 GMT - Innovation in China's healthcare sector should remain a key theme for 2026 despite recent underperformance, which Nomura analyst Jialin Zhang attributes to profit-taking. Zhang expects out-licensing activity to stay strong, supported by continued research and development investment, sustained cost and efficiency advantages over overseas peers, and fewer geopolitical hurdles following the recent U.S.-China trade truce. Zhang says it is critical to monitor the clinical progress of out-licensed assets next year, including data readouts and the speed of clinical trials. RNAi-based therapies could drive the next wave of out-licensing after weight-loss and oncology treatments, he adds, with IPO filings from RNAi companies potentially drawing further investor interest to the segment. Nomura tips Hengrui, Innovent, BeOne Medicines, Wuxi XDC and Mindray as its sector picks. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","XLV":"健康照护类股ETF-SPDR","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4588":"碎股","HCSG":"Healthcare Svcs Group Inc","BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","BK4581":"高盛持仓","BK4137":"综合支持服务"},"translate_title":"中国医疗保健行业的授权将保持强劲——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"LABU":0.6,"XBI":0.6,"HCSG":1.5},"content_text":"0931 GMT - Innovation in China's healthcare sector should remain a key theme for 2026 despite recent underperformance, which Nomura analyst Jialin Zhang attributes to profit-taking. Zhang expects out-licensing activity to stay strong, supported by continued research and development investment, sustained cost and efficiency advantages over overseas peers, and fewer geopolitical hurdles following the recent U.S.-China trade truce. Zhang says it is critical to monitor the clinical progress of out-licensed assets next year, including data readouts and the speed of clinical trials. RNAi-based therapies could drive the next wave of out-licensing after weight-loss and oncology treatments, he adds, with IPO filings from RNAi companies potentially drawing further investor interest to the segment. Nomura tips Hengrui, Innovent, BeOne Medicines, Wuxi XDC and Mindray as its sector picks. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 04:31 ET (09:31 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591600991","isCrawlerRequest":true}